Behrman Sells WIL for $500 Million

Behrman Capital has sold WIL Research Holdings Co. to an undisclosed financial sponsor for $500 million. WIL is an interdisciplinary non-clinical contract research organizations, providing product safety and toxicological assessment research and services primarily to the pharmaceutical, biotechnology, chemical and agricultural industries. Behrman says that the deal generated 3.6x cash-on-cash return, and a 63% IRR.